32194-76-6

Usage

Uses

Used in Pharmaceutical Industry:
3-(Methoxymethyl)benzoic acid is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new medications. Its potential anti-inflammatory and analgesic properties make it a compound of interest in the creation of novel therapeutic agents.
Used in Dye Industry:
In the dye industry, 3-(Methoxymethyl)benzoic acid is utilized as an intermediate in the production of various dyes, capitalizing on its chemical structure to enhance color properties and performance in different applications.
Used in Food Industry:
3-(Methoxymethyl)benzoic acid is employed as a flavoring agent in the food industry, where its unique chemical composition contributes to the taste and aroma of various food products, enhancing the overall sensory experience for consumers.
Used in Medicinal Development:
3-(Methoxymethyl)benzoic acid is studied for its potential in medicinal development, particularly for its possible anti-inflammatory and analgesic effects, which could lead to the discovery of new treatments for pain and inflammation-related conditions.

InChI:InChI=1/C9H10O3/c1-12-6-7-3-2-4-8(5-7)9(10)11/h2-5H,6H2,1H3,(H,10,11)

Upstream product

• 74-96-4 ethyl bromide 
• 1515-89-5 3-(methoxymethyl)bromobenzene 
• 1515-86-2 (3-Cyanophenyl)methyl methyl ether 
• 6515-58-8 3-bromomethylbenzoic acid 
• 67-56-1 methanol 
• 34040-63-6 methyl 3-(chloromethyl)benzoate 
• 124-41-4 sodium methylate 
• 1129-28-8 3-methoxycarbonylbenzyl bromide 
• 823-78-9 meta-bromobenzyl bromide 

Downstream Products

• 522622-95-3 3-(methoxymethyl)benzyl alcohol 
• 119858-82-1 m-chloromethyl(methoxymethyl)benzene 
• 199742-78-4 N-methoxy-3-(methoxymethyl)-N-methylbenzamide 
• 1161775-44-5 5-(3-methoxymethyl-phenyl)-oxazole-4-carboxylic acid methyl ester 
• 1373766-48-3 4-(bromomethyl)-5-(3-(methoxymethyl)phenyl)oxazole 
• 199742-77-3 3-(methoxymethyl)benzoyl chloride 
• 1373766-47-2 (5-(3-(methoxymethyl)phenyl)oxazole-4-yl)methanol 
• 1373766-53-0 4-(bromomethyl)-5-(3-(methoxymethyl)phenyl)-2-methyloxazole 
• 1373766-52-9 (5-(3-(methoxymethyl)phenyl)-2-methyloxazole-4-yl)methanol 
• 1373766-50-7 methyl 2-acetamido-3-(3-(methoxymethyl)phenyl)-3-oxopropanoate 
• 1373766-51-8 methyl 2-methyl-5-(3-(methoxymethyl)phenyl)oxazole-4-carboxylate 
• 1373766-49-4 methyl 2-amino-3-(3-(methoxymethyl)phenyl)-3-oxopropanoate 

Relevant academic research and scientific papers

Diaza-spiro[5.5]undecanes

The invention relates to compound of the formula I in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

Di/tri-aza-spiro-C9-C11alkanes

The invention relates to compounds of the formula I [in-line-formulae]A-D-C(R1)2—B??(I),[/in-line-formulae] in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

DI/TRI-AZA-SPIRO-C9-C11ALKANES

The invention relates to compounds of the formula I A-D-C(R1)2-B (I), in which A and B are aromatic ring systems and wherein D is selected from the groups D1 to D5 and the other substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES

The present invention relates to hydroximoyl-tetrazole derivatives of formula (I), their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions, wherein A represents a tetrazoyl group, Het represents a pyridyl group or a thiazolyl group and X represents various substituents.

2,3,4-trinor-1,5-inter-meta-phenylene-prostacyclin compounds useful in inhibiting thrombocyte aggregation

The invention relates to new 2,3,4-trinor-1,5-inter-m-phenylene-PGI2 derivatives of the formula (I) STR1 wherein A stands for carboxy, cyano, tetrazolyl or --COOR3 or --CONR1 R2 ; R3 is C1-4 alkyl or an equivalent of a pharmacologically acceptable cation: R1 and R2 each stands for hydrogen, phenyl; C1-5 alkyl, optionally substituted by carboxy, hydroxy, phenyl or C2-5 alkoxycarbonyl; or C1-4 alkylsulfonyl; or R1 and R2 together form an α,ω-alkylene chain containing 3-6 carbon atoms; B stands for oxygen or methylene; Y is optionally bromo-substituted vinylene or a --C C-- group: R4 stands for hydrogen or tetrahydro-pyran-2-yl; R5 represents an alkyl group containing 5-9 carbon atoms, which can be optionally interrupted by one or more oxygen atom(s) or --CH=CH-- or --C C-- group(s) and/or optionally substituted by halogen; or a phenyoxymethyl group optionally substituted by halogen or trifluoromethyl; or an alkenoyloxymethyl group containing 3-5 carbon atoms; R6 is hydrogen or C1-4 alkyl; R7 stands for hydrogen, halogen, cyano, C1-4 alkyl or C1-4 alkoxy; R8 is hydrogen, halogen, cyano, nitro, hydroxy or C2-5 alkanoylamido; with the proviso that if R5 stands for an alkyl group containing 5-9 carbon atoms which is unsubstituted or not interrupted by an oxygen atom or a --CH=CH-- or --C C-- group; or a phenyoxymethyl group optionally substituted by halogen or trifluoromethyl, then either R7 or R8 is other than hydrogen, or A is other than carboxy or --COOR3 and a process for the preparation thereof. The new compounds of the Formula I exhibit prolonged cytoprotecting and aggregation inhibiting and a low hypotensive effect and are superior to prostacycline in the prolonged duration of their activity.